SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to recent Saudi FDA approval for its Anktiva treatment in both lung and bladder cancer, marking a significant global expansion, alongside positive clinical updates for its CAR-NK program. This flurry of news has sparked immense trading volume and strong bullish sentiment, with the community eagerly discussing the potential for a short squeeze and the long-term impact of its innovative cancer therapies.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news that a major investor acquired a 91% stake, sparking widespread speculation about a potential delisting or privatization to reduce operational costs. This significant ownership concentration has ignited intense community debate, with many discussing the potential for a monumental short squeeze, while others caution about risks like dilution or market correction as traders weigh holding over the long weekend.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending as the community eagerly anticipates its Super App launch and discusses recent integrations, including a notable partnership with World Liberty Finance for on-chain payroll and card services. Investors are highlighting its robust ISO 20022 and MiCA compliance, positioning it as an undervalued utility project with significant long-term growth potential in real-world payments.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is currently a focal point for investors, primarily due to intense market speculation about artificial intelligence potentially disrupting its established software ecosystem, a sentiment further amplified by recent analyst downgrades. This has sparked a sharp debate among the community; while many express significant concern over the company's long-term viability in an AI-driven landscape, others are seizing the opportunity, emphasizing Adobe's strong cash flow and market position as fundamentally undervalued.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending as it continues to hit multi-year lows, fueling widespread investor frustration and intense criticism directed at CEO Jeff Green for the stock's persistent decline. Despite arguments for strong company fundamentals and a robust position in the open internet ad tech sector, the community is sharply divided between those calling for a bottom and others bracing for further drops.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

The community is buzzing around Applovin's recent sharp decline, with many attributing it to "max pain" options manipulation and broader software sector weakness, despite multiple analyst upgrades and strong growth prospects for its AI-powered Axon Ads platform. This divergence is fueling active debate among traders, with some seeing a prime dip-buying opportunity while others warn of perceived overvaluation and potential regulatory risks. Traders are closely watching for a rebound, especially with upcoming earnings reports on the horizon.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is a major trending topic as its stock continues a steep decline, prompting widespread community frustration over perceived insider selling and impending lockup expiries. Many investors are questioning the company's long-term viability amid concerns about AI replacing design roles and its valuation compared to competitors like Adobe. However, a segment of the community views the sharp pullback as a unique buying opportunity, betting on Figma's strong product and market leadership in collaborative design.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending due to its pivotal shift toward AI and high-performance computing, highlighted by a new multi-year data center lease with AMD at its Rockdale facility and the acquisition of the underlying land. The community views this as a transformative strategic move, validating the company's potential as a major AI infrastructure provider and distinguishing it favorably against some peers in the sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is surging following its selection as a prime contract awardee for the U.S. Missile Defense Agency's SHIELD program, which is seen by the community as a significant validation for its unique direct-to-cell technology. Long-term holders are celebrating this 'Golden Dome' involvement, viewing it as a clear path to future revenue streams and a blow to short sellers, while eagerly awaiting further commercial and deployment news.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is seeing heightened discussion following a significant drop in New York's online sports betting revenue, leading to community speculation about competitive pressures from prediction markets. Adding to the volatility, the NCAA is pushing for a federal halt on college sports betting amidst integrity concerns, casting a shadow of regulatory uncertainty over a key market segment. These factors are fueling debate among investors, balancing immediate challenges against longer-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in discussions among retail traders.During regular trading hours on Thursday, The Wall Street Journal reported that Merck KGaA is nearing a $3.5 billion deal to acquire SpringWorks, which specializes in rare diseases and cancer.The report, citing people familiar with the matter, noted that the German giant had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-jumps-ahead-of-q4-2024-report/ch5uuz0RwZ">confirmed</a> in February that it was in advanced talks for the buyout, and the two parties have now agreed on a price close to $47 per share.After the closing bell, Merck <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-confirms-late-stage-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/b6bde507-964a-46d9-846d-9d15390345d9_en">confirmed</a> the report, saying the two parties were discussing a deal at around $47 per share. However, it added that they had neither made any final decision nor entered into a legally binding agreement.On Stocktwits, sentiment for SpringWorks jumped into the 'extremely bullish' zone, accompanied by a 657% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SWTX_sentiment_and_message_volume_as_of_April_24_png_712d46db30.webp" alt="SWTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>SWTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>Several watchers appeared dissatisfied with the offer, indicating some alignment with the after-hours dip on Thursday."$47 is a joke, surely?" wrote one user, adding that Pfizer should throw its hat into the ring of prospective buyers.<stembedurl>https://stocktwits.com/monoksop/message/612643957</stembedurl>However, others expressed some relief."What I get, I get. Won't be super happy or anything, but I'll take the W and move on," said one watcher.<stembedurl>https://stocktwits.com/Son_of_Shango/message/612642003</stembedurl>SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.The company's first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. It raked in $61.5 million in the fourth quarter of 2024.<a href="https://stocktwits.com/symbol/SWTX">SpringWorks' stock</a> has gained over 23% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Equity

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.


SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of  SpringWorks Therapeutics Inc  (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline since mid-January.&nbsp;Despite the drop, retail sentiment flipped to 'bullish' from 'neutral,' driven by renewed speculation about German healthcare giant Merck KGaA (MKGAY) confirming details about a buyout.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_March_10_cba5133a09.png" alt="SWTX sentiment and message volume March 10.png" width="1316" height="302"><figcaption>SWTX sentiment and message volume March 10. | source: Stocktwits</figcaption></figure>According to The Fly, Barclays analyst Peter Lawson noted that some investors had anticipated confirmation of an acquisition from Merck's earnings report last week.&nbsp;However, Merck's annual report, published Thursday, only acknowledged that discussions about a potential merger were at an advanced stage but stated that there was no certainty a deal would be signed.&nbsp;The absence of a definitive announcement left traders analyzing the language for clues.Adding to speculation, SpringWorks canceled its planned appearance at Barclays' healthcare conference this week, continuing a pattern of event withdrawals following the FDA approval of its lead drug, Gomekli, for treating neurofibromatosis type 1 (NF1).&nbsp;The company had previously backed out of an earnings call and another public event, fueling investor theories that a significant corporate development was underway.&nbsp;Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout.Retail traders on Stocktwits reacted strongly to these developments. Message volumes surged, and the company's follower count increased by 17.9%, the highest among all biotech stocks last week.&nbsp;Some investors speculated that an acquisition could be announced this week, with one suggesting a potential offer price of $120 per share — a 140% premium to SpringWorks' last closing price.&nbsp;<stembedurl>https://stocktwits.com/Aombeus/message/607327621</stembedurl>Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.<stembedurl>https://stocktwits.com/TheGunnerAB/message/607292647</stembedurl>According to Koyfin, short interest in SpringWorks has declined from 15.7% at the start of the year to 12.2% last week, suggesting that bearish bets against the stock have been easing.&nbsp;The company's shares currently trade at a 47% discount to the average analyst price target of $72.88. Five of the eight analysts covering SpringWorks have a ‘Buy’rating, while three rate it a ‘Strong Buy,’ according to Koyfin.Despite last week's sharp decline, SpringWorks remains up more than 36% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor optimism ahead of its quarterly earnings report due after the next session.The biopharmaceutical company, focused on treatments for rare diseases and cancer, is expected to report a narrowing of fourth-quarter (Q4) adjusted losses to $0.71 per share from $1.44 a year earlier.&nbsp;Meanwhile, revenue is projected to soar to $57.16 million from $5.4 million.On Stocktwits, sentiment remained firmly bullish, though message volumes dipped slightly.The stock’s retail following grew over 2% in the past week and more than 26% in the past month.Users noted that after-hours trading volumes spiked well above the daily average, signaling heightened interest.<stembedurl>https://stocktwits.com/patten1962/message/604919223</stembedurl>One trader posted: “Yet another sleepless night ahead. I hope this is the last, and we can all celebrate.”<stembedurl>https://stocktwits.com/StrangerTrades/message/604917416</stembedurl>Recent investor enthusiasm has been fueled by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-soars-on-acquisition-buzz/ch5EgKYRtu">reports</a> that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks. While no official confirmation has been made, there are hopes that a potential deal could be signed in the coming weeks.Last week, BofA Securities raised its price target on SWTX to $87 from $65, maintaining a Buy rating. The research firm cited FDA approval for SpringWorks’ lead asset, Gomekli, as a key growth driver.Gomekli, a MEK inhibitor, treats neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumor growth in nerve tissue.In addition, SpringWorks’ first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. Last month, the company pre-announced Q4 U.S. Ogsiveo sales of $61.5 million.Despite the bullish momentum, short interest on SpringWorks stock climbed from 15.7% at the start of the year to 19.4% last week, according to Koyfin data.Still, SWTX shares have surged over 53% year-to-date, far outpacing the S&amp;P 500’s 4.7% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation drove heavy trading.&nbsp;The stock is on track for its best day on record following a Reuters report that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company, according to people familiar with the matter.&nbsp;If discussions are successful, a deal could be signed in the coming weeks, though neither Springworks nor Merck have commented on the report yet.Springworks is a commercial-stage biopharmaceutical company developing treatments for severe rare diseases and cancer.&nbsp;Ogsiveo, the company's first FDA-approved therapy, is used in the U.S. to treat adult patients with progressing desmoid tumors who require systemic treatment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_Feb_10_3b1f0e47dd.png" alt="SWTX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>SWTX sentiment and message volume Feb 10 as of 12:10 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Springworks was 'extremely bullish' as message volume spiked, pushing the stock into the list of top trending symbols by late Monday morning.&nbsp;Retail traders flooded the platform with congratulatory messages for long-term holders, though some warned that a sharp pullback could occur if official statements refute the buyout rumors.<stembedurl>https://stocktwits.com/flanker30/message/603597464</stembedurl><stembedurl>https://stocktwits.com/AngusMacbeth/message/603598578</stembedurl>Last month, Springworks pre-announced fourth-quarter U.S. Ogsiveo sales of $61.5 million, exceeding TD Cowen's $57.0 million estimate and consensus expectations of $59.8 million. The brokerage had suggested that a buyout could be on the horizon.Springworks stock has risen 16% over the past 12 months. According to Koyfin data, its short interest stood at 18.4% as of the last check.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Springworks surges as Germany's Merck KGaA said to be targeting takeover

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s  Merck  (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

SWTX
SpringWorks Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SWTX News

SWTXSpringWorks Therapeutics Inc